Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2-Rb wild-type and knock-down in breast cancer cell lines.
Oliviero MarinelliEmanuela RomagnoliFederica MaggiMassimo NabissiConsuelo AmantiniMaria Beatrice MorelliMatteo SantoniNicola BattelliGiorgio SantoniPublished in: BMC cancer (2020)
Overall, the Rib/Eve concurrent therapy augmented the in vitro cytotoxic effect, compared to Rib/Eve sequential therapy or single treatments.